LIFE SCIENCES

• Alloy Therapeutics, a biotechnology ecosystem company, in a strategic collaboration and licensing agreement with Takeda to develop and commercialize the latter’s induced pluripotent stem cell (iPSC) driven CAR-T cell platform (iCAR-T) and CAR-NK platform (iCAR-NK) for cell therapy in oncology indications
• LigaChem Biosciences (KRX: 141080), a clinical stage biopharmaceutical company, in numerous collaboration agreements, including:
  • in two transactions involving the license of LigaChem technology to Ono Pharmaceutical (TSE/TYO: 4528), to grow Ono’s oncology portfolio: (i) an exclusive license to LCB97, a pre-clinical stage antibody-drug conjugate (ADC) aimed at being a first-in-class drug in the field of solid tumors, for upfront and milestone payments of up to $700 million, plus tiered royalties; and (ii) a research collaboration and license agreement to generate novel ADC candidates leveraging LigaChem’s ConjuAll™ ADC platform, granting Ono an exclusive global right to ADC candidates to be generated against multiple targets selected by Ono, for a target exclusivity fee, milestone payments, and tiered royalties
  • two exclusive worldwide antibody licensing deals with NovaRock Biotherapeutics for ADC Drug Development
  • a worldwide in-licensing transaction with Go Therapeutics for a new antibody platform designed for the development of ADCs
  • an antibody discovery agreement with Trican Biotechnology in which LigaChem will advance its proprietary pipeline of ADCs using antibodies generated by Trican 
• Novo Nordisk A/S (NYSE: NVO) in a collaboration, development and license agreement with Aspect Biosystems to develop up to four bioprinted tissue products for the treatment of diabetes and obesity, with $75 million upfront and up to $650 million in milestones per product, plus tiered royalties
• Daewoong Pharmaceutical (KRX: 069620) in multiple transactions, including:
  • its exclusive licensing agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor ‘Bersiporocin’ in Greater China region
  • its exclusive license agreement with and equity investment in Vitalli Bio, a portfolio company of Aditum Bio, for the development and commercialization of a first-in-class new drug targeting Bruton's Tyrosine Kinase (BTK) and Interleukin-2-inducible T-cell kinase (ITK)
• AcuraStem in a license agreement with Takeda (NYSE: TAK) to develop and commercialize PIKFYVE targeted therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS), for an upfront and milestone payments totaling up to $580 million, plus tiered royalties
• Ginkgo Bioworks (NYSE: DNA), the organism company, in various collaboration and license agreements, including:
  • with Merck (NYSE: MRK) to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient manufacturing efforts
  • with Novo Nordisk A/S (NYSE: NVO) to create novel expression hosts for pharmaceutical products
  • with Sumitomo Chemical Co. to significantly increase the production efficiency and sustainability of a key bio-based commercial product
  • with Biogen (Nasdaq: BIIB) to develop a next-generation recombinant adeno-associated virus (AAV) production platform
• MedRhythms, a digital therapeutic developer, in a license agreement with Biogen (Nasdaq: BIIB) to develop and commercialize MR-004, an investigational prescription software-as-a-medical device (SaMD)  for the potential treatment of gait deficits in multiple sclerosis, for $3 million in upfront payments and up to $117.5 million in potential milestone payment, plus royalties
• Intellia Therapeutics (Nasdaq: NTLA), a clinical-stage genome editing company with a proprietary CRISPR/Cas9 technology platform, in a strategic collaboration with SparingVision, a genomic medicine company based in France developing treatments for ocular diseases, to develop new ocular therapies addressing unmet medical needs
• Dicerna Pharmaceuticals (Nasdaq: DRNA) in numerous agreements, including:
  • a global collaboration agreement with Novo Nordisk A/S to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases for an upfront payment of $175 million, a $50 million equity investment and up to $357.5 million per target in development, regulatory, and commercialization milestone payments
  • a global collaboration and license agreement in excess of $1.67 billion in upfront and milestone payments, plus royalties, with F. Hoffmann-La Roche AG to develop and commercialize DCR-HBVS for the treatment of chronic Hepatitis B Virus (HBV) infection
• LG Chem Life Sciences in a $900+ million multi-target, strategic collaboration with CUE Biopharma that provides LG Chem with the Asia rights to Cue Biopharma’s lead immuno-oncology CUE-101 program, and products in the two other CUE-102 and CUE-103 programs as well as a worldwide option for another antigen focused biologic

ENERGY/RENEWABLES

• Advising energy client on a joint venture with Latin American based energy conglomerate.
• A major multinational client in “smart room” joint venture.

RESEARCH AND ACADEMIA

• Routinely advise emerging technology companies on early stage evaluation, services and research agreements with large and midsize pharma, biotech, device and other technology companies.
• Represent companies in-licensing IP from leading academic institutions, as well as prominent academic and research institutions in connection with out-licensing their intellectual property.
• Regularly negotiate sponsored research agreements, material transfer agreements, clinical trial agreements, grant agreements and other research and collaboration agreements involving academic and non-profit entities.